Expert interview with Dr Joaquim Bellmunt MD PhD conducted by Prof Gordon McVie

New targeted drugs for metastatic renal cell carcinoma

Target audience:

This educational activity is intended for medical, surgical and radiation oncologists, as well as allied oncology professionals who treat renal cell carcinoma.

Statement of need:

Metastatic renal cell carcinoma (RCC) has poor outcomes. Metastatic disease is resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy. Although targeted cancer therapies have improved progression-free survival for RCC they have not yet demonstrated much improvement in overall survival. What next after failure of these drugs? An educational need exists to assist physicians in the sequential use of novel treatments, or perhaps in the future, in combinations. The management of metastatic renal cell carcinoma has become more challenging and more complicated because some therapeutic successes have been reported in this stubborn cancer.

Learning objective:

After watching this expert interview participants should be able to:

• Understand the pathophysiology of renal cancer, newly detected cancer associated molecular targets and new therapeutics designed to lock on to those receptors or cellular proteins.
• Have insight into the use of the new molecules, in sequence, in combination with other modalities such as immunomodulators, or in combination with each other, together with expectations of side effects and gains in symptom/free survival when given to patients with metastatic or locally progressive renal cancer.

 

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.

This material was developed for use outside of the US and is to be used in accordance with local laws and regulations.

Supported by an unrestricted educational grant from Novartis